United States Biotechnology & Medical Research

Alaunos Therapeutics Inc (TCRT)

Track

Track

Alaunos Therapeutics Inc. recorded its most recent insider trading activity on December 31, 2024. During this period, Jaime Vieser executed two separate sell transactions involving a total of 3,000 shares. No further market movements by company insiders have been reported since that date.
Ticker: TCRT Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Alaunos Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
1.7
Vieser Jaime Non-Executive Director
Transaction date
Sale
Price
233.97
Quantity 1,609 +49.8%
Value US$2,911,950
1.7
Vieser Jaime Non-Executive Director
Transaction date
Sale
Price
239.02
Quantity 61,112 -27.0%
Value US$167,197
0.9
Boyle Kevin S. Sr. Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
48.12
Quantity 11,579 +1.3%
Value US$4,522,844
0.9
Boyle Kevin S. Sr. Officer Officer
Transaction date
Proposed sale
Price
0.14
Quantity 70,401
Value US$9,504
1.9
Postma Robert W Non-Executive Director
Transaction date
Purchase
Price
0.65
Quantity 750,000 +17.6%
Value US$487,500
1.7
Vieser Jaime Non-Executive Director
Transaction date
Purchase
Price
0.65
Quantity 1,250,000 +inf%
Value US$812,500
0.9
Boyle Kevin S. Sr. Chief Executive Officer Executive Director
Transaction date
Purchase
Price
1.40
Quantity 9,116 +1.0%
Value US$12,762
0.9
Boyle Kevin S. Sr. Chief Executive Officer Executive Director
Transaction date
Purchase
Price
1.40
Quantity 884 +0.1%
Value US$1,238
1.7
Vieser Jaime Non-Executive Director
Transaction date
Purchase
Price
1.91
Quantity 100,000 +16.5%
Value US$191,000
1.9
Postma Robert W Non-Executive Director
Transaction date
Purchase
Price
1.73
Quantity 54,492 +1.3%
Value US$94,271
1.9
Postma Robert W Non-Executive Director
Transaction date
Purchase
Price
1.73
Quantity 20,508 +1.7%
Value US$35,479
Buck Jill EVP, GM Gene Therapy Officer
Transaction date
Planned sale
Price
3.12
Quantity 27,894 -12.3%
Value US$87,029
Lafond Kevin G SVP, Treasurer & CAO Officer
Transaction date
Planned sale
Price
3.09
Quantity 18,020 -22.0%
Value US$55,682
Hadfield Robert General Counsel and Secretary Officer
Transaction date
Planned sale
Price
3.12
Quantity 26,500 -16.6%
Value US$82,680
De Groot Eleanor EVP, GM Cell Therapy Officer
Transaction date
Planned sale
Price
2.72
Quantity 21,620 -9.5%
Value US$58,806
Cooper Laurence James Neil President and CEO Executive Director
Transaction date
Planned sale
Price
2.71
Quantity 105,693 -5.5%
Value US$286,428
MAUNEY DAVID M MD President Officer
Transaction date
Planned sale
Price
4.55
Quantity 22,394 -10.3%
Value US$101,893
Buck Jill EVP, GM Gene Therapy Officer
Transaction date
Planned sale
Price
4.55
Quantity 27,923 -13.8%
Value US$127,050
De Groot Eleanor EVP, GM Cell Therapy Officer
Transaction date
Planned sale
Price
4.55
Quantity 24,890 -12.5%
Value US$113,250
Hadfield Robert General Counsel and Secretary Officer
Transaction date
Planned sale
Price
4.55
Quantity 16,853 -14.3%
Value US$76,681
Lafond Kevin G SVP, Treasurer & CAO Officer
Transaction date
Planned sale
Price
4.55
Quantity 21,570 -25.2%
Value US$98,144
Cooper Laurence James Neil Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
4.88
Quantity 110,694 -6.0%
Value US$540,187
Lafond Kevin G SVP, Treasurer & CAO
Transaction date
Planned sale
Price
5.25
Quantity 11,667 -12.0%
Value US$61,252
Cooper Laurence James Neil Chief Executive Officer
Transaction date
Purchase
Price
4.68
Quantity 6,440 +0.6%
Value US$30,139
MAUNEY DAVID M MD EVP and Chief Business Officer
Transaction date
Purchase
Price
4.68
Quantity 4,270 +7.9%
Value US$19,984
BELBEL CAESAR J COO, CLO, and Secretary Officer
Transaction date
Sale
Price
12.84
Quantity 153,333 -72.1%
Value US$1,968,796
LEBEL FRANCOIS Executive Vice President R&D Officer
Transaction date
Sale
Price
10.12
Quantity 50,000 -100.0%
Value US$506,000
BRENNAN MURRAY Non-Executive Director
Transaction date
Sale
Price
9.55
Quantity 5,837 -31.8%
Value US$55,743
Lafond Kevin G Vice Pres., Treasurer, & CAO Officer
Transaction date
Sale
Price
9.70
Quantity 27,500 -100.0%
Value US$266,750
Lafond Kevin G Vice Pres., Treasurer, & CAO Officer
Transaction date
Sale
Price
9.70
Quantity 3,334 -100.0%
Value US$32,340
BRENNAN MURRAY Non-Executive Director
Transaction date
Sale
Price
9.72
Quantity 34,163 -65.1%
Value US$332,064
Lafond Kevin G Vice Pres., Treasurer, & CAO Officer
Transaction date
Sale
Price
9.60
Quantity 26,666 -100.0%
Value US$255,994
KIRK RANDAL J Non-Executive Director Large shareholder
Transaction date
Purchase
Price
8.75
Quantity 1,440,000 +8.8%
Value US$12,600,000
KIRK RANDAL J Non-Executive Director Large shareholder
Transaction date
Purchase
Price
3.50
Quantity 2,857,143 +21.1%
Value US$10,000,000
KIRK RANDAL J Non-Executive Director Large shareholder
Transaction date
Purchase
Price
5.20
Quantity 1,923,075 +24.1%
Value US$9,999,990
KIRK RANDAL J Non-Executive Director Large shareholder
Transaction date
Purchase
Price
4.99
Quantity 38,294 +2.9%
Value US$191,087
KIRK RANDAL J Non-Executive Director Large shareholder
Transaction date
Purchase
Price
4.91
Quantity 110,792 +9.3%
Value US$543,989
KIRK RANDAL J Non-Executive Director Large shareholder
Transaction date
Purchase
Price
4.91
Quantity 197,376 +19.7%
Value US$969,116
KIRK RANDAL J Non-Executive Director Large shareholder
Transaction date
Purchase
Price
4.95
Quantity 153,478 +18.1%
Value US$759,716
Fowler Wyche Non-Executive Director
Transaction date
Purchase
Price
5.19
Quantity 5,000 +7.4%
Value US$25,926
KIRK RANDAL J Non-Executive Director Large shareholder
Transaction date
Purchase
Price
5.13
Quantity 285,518 +50.9%
Value US$1,464,707
KIRK RANDAL J Non-Executive Director Large shareholder
Transaction date
Purchase
Price
4.58
Quantity 444,892 +383.2%
Value US$2,037,605
KIRK RANDAL J Non-Executive Director Large shareholder
Transaction date
Purchase
Price
4.65
Quantity 116,112 +inf%
Value US$539,921
KIRK RANDAL J Non-Executive Director Large shareholder
Transaction date
Purchase
Price
5.75
Quantity 1,910,000 +31.5%
Value US$10,982,500
KIRK RANDAL J Non-Executive Director Large shareholder
Transaction date
Purchase
Price
4.80
Quantity 2,426,235 +inf%
Value US$11,645,928
MCINERNEY TIMOTHY Non-Executive Director
Transaction date
Purchase
Price
3.10
Quantity 50,000 +31.6%
Value US$155,000
CANNON JAMES ANTHONY Non-Executive Director
Transaction date
Purchase
Price
3.10
Quantity 175,000 +388.9%
Value US$542,500
ESSEX WOODLANDS HEALTH VENTURES FUND VI L P Large shareholder
Transaction date
Purchase
Price
3.10
Quantity 129,000 +5.8%
Value US$399,900
ESSEX WOODLANDS HEALTH VENTURES FUND VI L P Large shareholder
Transaction date
Purchase
Price
1.83
Quantity 328,766 +17.2%
Value US$599,998
MCINERNEY TIMOTHY Non-Executive Director
Transaction date
Purchase
Price
1.83
Quantity 50,000 +63.9%
Value US$91,250
LEWIS JONATHAN CEO Executive Director
Transaction date
Purchase
Price
3.00
Quantity 3,000 +150.0%
Value US$8,990
MCINERNEY TIMOTHY Non-Executive Director
Transaction date
Purchase
Price
5.00
Quantity 4,000 +6.8%
Value US$20,000
LEWIS JONATHAN CEO Executive Director
Transaction date
Purchase
Price
4.95
Quantity 2,000 +inf%
Value US$9,900
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-01-03 2024-12-31 S Sale
1.7
Vieser Jaime
Non-Executive Director
1,609 +49.8%
233.97
US$2,911,950 		1,609 +49.8% 233.97 US$2,911,950
2025-01-03 2024-12-31 S Sale
1.7
Vieser Jaime
Non-Executive Director
61,112 -27.0%
239.02
US$167,197 		61,112 -27.0% 239.02 US$167,197
2023-09-05 2023-09-01 PlS Planned sale
0.9
Boyle Kevin S. Sr.

Chief Executive Officer

Executive Director
11,579 +1.3%
48.12
US$4,522,844 		11,579 +1.3% 48.12 US$4,522,844
2023-09-01 2023-09-01 PrS Proposed sale
0.9
Boyle Kevin S. Sr.

Officer

Officer
70,401
0.14
US$9,504 		70,401 0.14 US$9,504
2022-12-01 2022-11-29 B Purchase
1.9
Postma Robert W
Non-Executive Director
750,000 +17.6%
0.65
US$487,500 		750,000 +17.6% 0.65 US$487,500
2022-12-01 2022-11-29 B Purchase
1.7
Vieser Jaime
Non-Executive Director
1,250,000 +inf%
0.65
US$812,500 		1,250,000 +inf% 0.65 US$812,500
2021-11-17 2021-11-17 B Purchase
0.9
Boyle Kevin S. Sr.

Chief Executive Officer

Executive Director
9,116 +1.0%
1.40
US$12,762 		9,116 +1.0% 1.40 US$12,762
2021-11-17 2021-11-16 B Purchase
0.9
Boyle Kevin S. Sr.

Chief Executive Officer

Executive Director
884 +0.1%
1.40
US$1,238 		884 +0.1% 1.40 US$1,238
2021-10-04 2021-09-29 B Purchase
1.7
Vieser Jaime
Non-Executive Director
100,000 +16.5%
1.91
US$191,000 		100,000 +16.5% 1.91 US$191,000
2021-09-03 2021-09-02 B Purchase
1.9
Postma Robert W
Non-Executive Director
54,492 +1.3%
1.73
US$94,271 		54,492 +1.3% 1.73 US$94,271
2021-09-03 2021-09-02 B Purchase
1.9
Postma Robert W
Non-Executive Director
20,508 +1.7%
1.73
US$35,479 		20,508 +1.7% 1.73 US$35,479
2021-01-12 2021-01-08 PlS Planned sale
Buck Jill

EVP, GM Gene Therapy

Officer
27,894 -12.3%
3.12
US$87,029 		27,894 -12.3% 3.12 US$87,029
2021-01-12 2021-01-08 PlS Planned sale
Lafond Kevin G

SVP, Treasurer & CAO

Officer
18,020 -22.0%
3.09
US$55,682 		18,020 -22.0% 3.09 US$55,682
2021-01-12 2021-01-08 PlS Planned sale
Hadfield Robert

General Counsel and Secretary

Officer
26,500 -16.6%
3.12
US$82,680 		26,500 -16.6% 3.12 US$82,680
2021-01-06 2021-01-04 PlS Planned sale
De Groot Eleanor

EVP, GM Cell Therapy

Officer
21,620 -9.5%
2.72
US$58,806 		21,620 -9.5% 2.72 US$58,806
2021-01-06 2021-01-04 PlS Planned sale
Cooper Laurence James Neil

President and CEO

Executive Director
105,693 -5.5%
2.71
US$286,428 		105,693 -5.5% 2.71 US$286,428
2020-01-03 2020-01-02 PlS Planned sale
MAUNEY DAVID M MD

President

Officer
22,394 -10.3%
4.55
US$101,893 		22,394 -10.3% 4.55 US$101,893
2020-01-03 2020-01-02 PlS Planned sale
Buck Jill

EVP, GM Gene Therapy

Officer
27,923 -13.8%
4.55
US$127,050 		27,923 -13.8% 4.55 US$127,050
2020-01-03 2020-01-02 PlS Planned sale
De Groot Eleanor

EVP, GM Cell Therapy

Officer
24,890 -12.5%
4.55
US$113,250 		24,890 -12.5% 4.55 US$113,250
2020-01-03 2020-01-02 PlS Planned sale
Hadfield Robert

General Counsel and Secretary

Officer
16,853 -14.3%
4.55
US$76,681 		16,853 -14.3% 4.55 US$76,681
2020-01-03 2020-01-02 PlS Planned sale
Lafond Kevin G

SVP, Treasurer & CAO

Officer
21,570 -25.2%
4.55
US$98,144 		21,570 -25.2% 4.55 US$98,144
2019-12-31 2019-12-30 PlS Planned sale Cooper Laurence James Neil

Chief Executive Officer

Executive Director
110,694 -6.0%
4.88
US$540,187 		110,694 -6.0% 4.88 US$540,187
2019-11-27 2019-11-26 PlS Planned sale
Lafond Kevin G

SVP, Treasurer & CAO
11,667 -12.0%
5.25
US$61,252 		11,667 -12.0% 5.25 US$61,252
2017-11-09 2017-11-08 B Purchase Cooper Laurence James Neil

Chief Executive Officer
6,440 +0.6%
4.68
US$30,139 		6,440 +0.6% 4.68 US$30,139
2017-11-09 2017-11-08 B Purchase MAUNEY DAVID M MD

EVP and Chief Business Officer
4,270 +7.9%
4.68
US$19,984 		4,270 +7.9% 4.68 US$19,984
2015-11-23 2015-11-19 S Sale BELBEL CAESAR J

COO, CLO, and Secretary

Officer
153,333 -72.1%
12.84
US$1,968,796 		153,333 -72.1% 12.84 US$1,968,796
2015-06-11 2015-06-09 S Sale LEBEL FRANCOIS

Executive Vice President R&D

Officer
50,000 -100.0%
10.12
US$506,000 		50,000 -100.0% 10.12 US$506,000
2015-06-05 2015-06-04 S Sale BRENNAN MURRAY Non-Executive Director
5,837 -31.8%
9.55
US$55,743 		5,837 -31.8% 9.55 US$55,743
2015-06-05 2015-06-03 S Sale Lafond Kevin G

Vice Pres., Treasurer, & CAO

Officer
27,500 -100.0%
9.70
US$266,750 		27,500 -100.0% 9.70 US$266,750
2015-06-05 2015-06-03 S Sale Lafond Kevin G

Vice Pres., Treasurer, & CAO

Officer
3,334 -100.0%
9.70
US$32,340 		3,334 -100.0% 9.70 US$32,340
2015-06-05 2015-06-03 S Sale BRENNAN MURRAY Non-Executive Director
34,163 -65.1%
9.72
US$332,064 		34,163 -65.1% 9.72 US$332,064
2015-06-05 2015-06-03 S Sale Lafond Kevin G

Vice Pres., Treasurer, & CAO

Officer
26,666 -100.0%
9.60
US$255,994 		26,666 -100.0% 9.60 US$255,994
2015-02-10 2015-02-09 B Purchase KIRK RANDAL J Non-Executive Director Large shareholder
1,440,000 +8.8%
8.75
US$12,600,000 		1,440,000 +8.8% 8.75 US$12,600,000
2013-10-31 2013-10-29 B Purchase KIRK RANDAL J Non-Executive Director Large shareholder
2,857,143 +21.1%
3.50
US$10,000,000 		2,857,143 +21.1% 3.50 US$10,000,000
2012-01-23 2012-01-20 B Purchase KIRK RANDAL J Non-Executive Director Large shareholder
1,923,075 +24.1%
5.20
US$9,999,990 		1,923,075 +24.1% 5.20 US$9,999,990
2011-08-25 2011-08-23 B Purchase KIRK RANDAL J Non-Executive Director Large shareholder
38,294 +2.9%
4.99
US$191,087 		38,294 +2.9% 4.99 US$191,087
2011-08-22 2011-08-22 B Purchase KIRK RANDAL J Non-Executive Director Large shareholder
110,792 +9.3%
4.91
US$543,989 		110,792 +9.3% 4.91 US$543,989
2011-08-22 2011-08-19 B Purchase KIRK RANDAL J Non-Executive Director Large shareholder
197,376 +19.7%
4.91
US$969,116 		197,376 +19.7% 4.91 US$969,116
2011-08-22 2011-08-18 B Purchase KIRK RANDAL J Non-Executive Director Large shareholder
153,478 +18.1%
4.95
US$759,716 		153,478 +18.1% 4.95 US$759,716
2011-08-11 2011-08-10 B Purchase Fowler Wyche Non-Executive Director
5,000 +7.4%
5.19
US$25,926 		5,000 +7.4% 5.19 US$25,926
2011-08-09 2011-08-09 B Purchase KIRK RANDAL J Non-Executive Director Large shareholder
285,518 +50.9%
5.13
US$1,464,707 		285,518 +50.9% 5.13 US$1,464,707
2011-08-09 2011-08-08 B Purchase KIRK RANDAL J Non-Executive Director Large shareholder
444,892 +383.2%
4.58
US$2,037,605 		444,892 +383.2% 4.58 US$2,037,605
2011-08-09 2011-08-05 B Purchase KIRK RANDAL J Non-Executive Director Large shareholder
116,112 +inf%
4.65
US$539,921 		116,112 +inf% 4.65 US$539,921
2011-02-07 2011-02-03 B Purchase KIRK RANDAL J Non-Executive Director Large shareholder
1,910,000 +31.5%
5.75
US$10,982,500 		1,910,000 +31.5% 5.75 US$10,982,500
2011-01-14 2011-01-12 B Purchase KIRK RANDAL J Non-Executive Director Large shareholder
2,426,235 +inf%
4.80
US$11,645,928 		2,426,235 +inf% 4.80 US$11,645,928
2009-12-11 2009-12-09 B Purchase MCINERNEY TIMOTHY Non-Executive Director
50,000 +31.6%
3.10
US$155,000 		50,000 +31.6% 3.10 US$155,000
2009-12-11 2009-12-09 B Purchase CANNON JAMES ANTHONY Non-Executive Director
175,000 +388.9%
3.10
US$542,500 		175,000 +388.9% 3.10 US$542,500
2009-12-10 2009-12-08 B Purchase ESSEX WOODLANDS HEALTH VENTURES FUND VI L P Large shareholder
129,000 +5.8%
3.10
US$399,900 		129,000 +5.8% 3.10 US$399,900
2009-12-10 2009-09-15 B Purchase ESSEX WOODLANDS HEALTH VENTURES FUND VI L P Large shareholder
328,766 +17.2%
1.83
US$599,998 		328,766 +17.2% 1.83 US$599,998
2009-09-17 2009-09-15 B Purchase MCINERNEY TIMOTHY Non-Executive Director
50,000 +63.9%
1.83
US$91,250 		50,000 +63.9% 1.83 US$91,250
2007-12-10 2007-12-07 B Purchase LEWIS JONATHAN

CEO

Executive Director
3,000 +150.0%
3.00
US$8,990 		3,000 +150.0% 3.00 US$8,990
2007-03-22 2007-03-15 B Purchase MCINERNEY TIMOTHY Non-Executive Director
4,000 +6.8%
5.00
US$20,000 		4,000 +6.8% 5.00 US$20,000
2007-03-14 2007-03-12 B Purchase LEWIS JONATHAN

CEO

Executive Director
2,000 +inf%
4.95
US$9,900 		2,000 +inf% 4.95 US$9,900
Explore more

More insider trading research around Alaunos Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America